Full text is available at the source.
Abstract
Evidence evaluates the effects of combined sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiometabolic outcomes in type 2 diabetes.
- Combining SGLT2 inhibitors and GLP-1 receptor agonists may influence cardiometabolic health.
- The focus is on outcomes related to heart and metabolic function.
- Practical treatment approaches for managing type 2 diabetes are considered.
Simplified